

AD_____

AWARD NUMBER: W81XWH-05-1-0016

TITLE: Antibody-based Drug Carriers for Targeted Prostate Cancer Chemotherapy

PRINCIPAL INVESTIGATOR: Gennady Gololobov, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas Health Science Center
Houston, Texas 77030-3900

REPORT DATE: May 2006

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-05-2006		2. REPORT TYPE Final		3. DATES COVERED (From - To) 31 Oct 2004 – 30 Apr 2006	
4. TITLE AND SUBTITLE Antibody-based Drug Carriers for Targeted Prostate Cancer Chemotherapy				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0016	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Gennady Gololobov, Ph.D. E-Mail: ggololobov@gmail.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas Health Science Center Houston, Texas 77030-3900				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goal of this project is to generate a library of human antibody Fvs containing prostate tissue homing peptide for specific delivery of chemotherapeutic drug doxorubicin to the site of prostate cancer. We have replaces CDR 3 loop of the antibody VL domain with the sequence encoding prostate tissue homing peptide. Panning of the library with doxorubicin conjugated to BSA yielded a panel of monoclonal doxorubicin specific Fvs that could be used as prostate tissue specific carrier of this drug with increased tissue selectivity and reduced toxicity.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	6
References.....	6
Appendices.....	7

INTRODUCTION:

The goal of the project was to create a universal, antibody-based drug delivery system for targeted delivery of small chemotherapeutic drugs to the site of prostate cancer. We wanted to explore the ability of the antibodies to reversibly hold small organic molecules (haptens) via non-covalent interactions with six flexible polypeptide loops (CDRs). Binding of this class of molecules including chemotherapeutic drugs usually does not required participation of all six CDR loops. We proposed to use these unutilized CDR loops for targeting such antibody-carrier to the cancer site by replacing it with loop-shaped peptide specific to the cancer site. In the first specific aim we modified the existing human phage display library by introducing a prostate-homing peptide into the 3rd CDR loop of the light chain. The modified library was used to select a group of Fvs specific for a model chemotherapeutic drug, doxorubicin (DOX). Selected Fvs were characterized for their affinity to DOX using spectrofluorometric measurements. In the second specific aim we evaluate the potential of selected Fvs to deliver DOX to the prostate tissue in mice.

BODY.

Task 1. **To generate a panel of DOX-specific Fvs containing prostate homing peptide (Month 1-12):**

a. Introduce a prostate homing sequence, SMSIARL, into human semi-synthetic Fv phage library (Months 1-3). Prostate homing sequence will be introduced into the set of antibody VL-genes by two step PCR. Modified VLs will be cloned into the library in pHEN2 phagemid vector. The efficiency of the cloning will be verified by colony PCR and sequencing. The sequence encoding prostate homing peptide, TCA ATG TCA ACT GCT AGG CTG, was introduced into CDR3 of VL domains (both κ and λ) of Griffin 1 human semi-synthetic Fv library [1] in two PCR steps. The methods described in [2] with certain modification were applied. VH and VL parts of the Fv insert in this library are inserted into pHEN2 vector at separate cloning sites (*Sfi I* and *Apa LI* for VH, and *Xho I* and *Not I* for VL) permitting selective removal of one domain without affecting another. The vector also contains the following sequence elements: a signal peptide, a gene3 structural peptide, a stop codon (amber) between the insert and gene3, a *c-myc* peptide tag, poly(his)₆, an IPTG-inducible lac promoter and an ampicillin resistance gene. The amber codon permits secretion of soluble Fv or their expression as p3-fusion proteins on the phage surface, depending on the strain of host *E. coli* (HB2151 cells recognize amber as a stop and TG1 cells recognize amber as Glu). A single back primer containing the sequence of invariable 15-mer Fv linker and *Xho I* restriction site was used in all amplifications. VL genes were obtained by digesting the library with *Apa LI* and *Not I* to preserve the sequence of peptide linker needed for back primer annealing. In the first step VLs were PCR-amplified using 23 V- κ and 23 V- λ forward primers (residues 88-94, Kabat numbering) which represent C-terminal sequence diversity of 26 κ and 31 λ germline genes composing the VL part of the Fv library [1]. Each primer had antisense sequence encoding prostate homing peptide at the 3'-end. In the second PCR step VLs were re-amplified using two forward primers containing antisense sequences encoding prostate homing peptide, conserved FW4 regions of kappa and lambda chains and *Not I* cloning site (See Figure 1). Following completion of the PCR, the amplified DNA bands of the correct size were cut from agarose gels, extracted using GeneClean II (BIO 101) and quantitated by EtBr fluorescence (λ_{em} 590 nm, λ_{ex} 302 nm). Modified VL DNA containing prostate homing sequence was sequentially digested with *Xho I* and *Not I* and inserted into pHEN 2 vector containing the original Fv library digested with the same enzymes. Host cells were transformed by electroporation, clones were selected in ampicillin and the presence of inserts in individual colonies were confirmed by PCR using primers located in the vector upstream and downstream of the insert, yielding EtBr-stained bands at 0.9 kb (See Figure 2). Addition of helper phage (VCSM13) containing a kanamycin resistant gene permits packaging of phage particles from TG1 cell cultures containing both ampicillin and kanamycin. The particles in the supernatant of the culture were precipitated twice with 3% PEG/0.5 M NaCl, yielding phage ready for the selections.

b. Isolate a panel (8-10 different clones) of DOX-specific Fv-phages (Months 4-9). Clones will be selected by panning the library over DOX-BSA conjugate. DOX-specific clones will be identified by phage ELISA. DOX specificity will be confirmed for these Fvs expressed in soluble form. DOX was conjugated to BSA or ovalbumin via its amino-group by carbodiimide coupling [11]. Phages (10^{12} cfu/ml in PBS, 0.5 M NaCl, 100 μ l) were pre-adsorbed on BSA to deplete any BSA binding clones and incubated over Maxisorb Immuntubes coated with DOX-BSA conjugate for 30 min. After several washes with PBS, 0.5 M NaCl, 0.02% Tween-20, bound phages were eluted with 0.1 M Gly-HCl buffer, pH 2.5, immediately neutralized with Tris-base and used to re-infect TG1 or HB2151 cells. After two and five rounds of selection approximately 100 Fv clones expressing soluble Fvs were assayed for DOX binding with DOX-ovalbumin conjugate by ELISA (See Figure 3). 10 DOX-

specific clones were sequenced and analyzed for assignment of class and family according to homologies with sequences in the Kabat database (See Table 1).

Task 2. To conduct biodistribution studies of free DOX and Dox-Fv complexes (Month 13-18):

This task was not accomplished because on 11/04/05 PI has resigned his position at UTHSCH.

KEY RESEARCH ACCOMPLISHMENTS.

- Generated a library of human Fvs containing prostate tissue homing peptide in place of VL CDR 3.
- Selected a panel of DOX binding Fv that could be used as a carriers for prostate tissue specific delivery of DOX.

REPORTABLE OUTCOME.

PI was offered a position to lead Antibody Engineering group at Lexicon Genetics Inc. in part based on the experience he obtained while conducting research under this award.

CONCLUSION.

We have generated a panel of prostate tissue homing Fvs that could serve as carriers for tissue specific delivery of chemotherapeutic drug doxorubicin. Their in vivo efficacy still needs to be tested.

REFERENCES.

1. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. *EMBO J.* 13:3245-3260. 1994.
2. Paul S, Tramontano A, Gololobov G, Zhou YX, Taguchi H, Karle S, Nishiyama Y, Planque S, George S. Phosphonate ester probes for proteolytic antibodies. *J Biol Chem.* 276:28314-28320, 2001.

APPENDICES.

None

SUPPORTING DATA.




Fig.1 Amplification of VL kappa and lambda domains containing CDR3 replaced with prostate homing peptide




Fig.2 Colony PCR confirming presence of Fv-inserts in the Fv phage display library containing prostate tissue homing peptide.




Fig. 3 Enrichment of the library with DOX-binding clones after second and fifth rounds of panning with DOX-BSA conjugates determined by ELISA with soluble monoclonal Fvs.

Table 1: Germline gene assignment for selected DOX-binding Fv clones:

Clone	Heavy chain	Light chain
A2	VH3-23 519 e-150 VH3-53 422 e-121 VH3-66 398 e-113	V1-16 565 e-163 V1-17 525 e-152 V1-11 422 e-121
A3	VH3-23 559 e-162 VH3-53 412 e-118 VH3-48 408 e-116	V2-13 553 e-160
A4	VH3-23 551 e-159 VH3-53 404 e-115 VH3-48 400 e-114	V2-13 553 e-160
A5	VH3-23 549 e-159 VH3-53 402 e-115 VH3-48 398 e-113	V2-13 559 e-162
A6	VH3-20 511 e-147 VH3-9 391 e-111 VH3-23 337 4e-95	V1-16 500 e-144 V1-17 460 e-132 V1-11 357 e-101
A7	VH6-1 595 e-172	V2-13 571 e-165
A8	VH1-45 543 e-157 VH1-2 313 6e-88 VH1-46 305 1e-85	V2-13 561 e-162
A9	VH1-69 567 e-164 VH1-18 337 4e-95 VH1-8 329 1e-92	V2-13 553 e-160